期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

奥氮平与齐拉西酮对老年痴呆患者糖脂代谢的影响 被引量：12

原文传递
导出
摘要 目的探讨奥氮平与齐拉西酮对老年痴呆伴精神障碍患者血糖、血脂的影响。方法将86例老年痴呆伴精神障碍患者随机分为2组,每组各43例,分别给予齐拉西酮和奥氮平治疗12周,采用简明精神病量表(BPRS)评定临床疗效,在治疗前及治疗第4、8、12周末对血糖、血脂、体重进行检测及分析。结果(1)奥氮平组与齐拉西酮组BPRS减分率之间无显著性差异(P>0.05);(2)齐拉西酮组治疗前后空腹和餐后2h血糖、低密度脂蛋白胆固醇、甘油三酯、体重指数差异均无显著性(P>0.05),而奥氮平组治疗后上述各项水平明显升高,与治疗前比较均有显著性差异(P<0.05或0.01)。结论奥氮平和齐拉西酮治疗老年痴呆伴精神障碍的疗效相当;齐拉西酮对患者的血糖、血脂影响较奥氮平小,适于心脑血管疾病及其高危人群伴精神障碍患者的长期使用。
作者 陈青 刘小林 陈友芝
机构地区 武汉市精神病医院
出处 《卒中与神经疾病》 2008年第6期369-371,共3页 Stroke and Nervous Diseases
关键词 奥氮平 齐拉西酮 体重 血糖 血脂 老年痴呆
分类号 R749.1 [医药卫生—神经病学与精神病学]
  • 相关文献

参考文献6

  • 1Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry, 2007,68 (Suppl 1 ) : 20-27.
  • 2Nasrallah HA. Metabolic findings from the CATIE trial and their relation to tolerability. CNS Speetr, 2006, 11 (7supp 17) : 32- 39.
  • 3金华 Jonathan M. Meyer Dilip V. Jeste.非典型抗精神病药:糖代谢紊乱和代谢综合征[J].上海精神医学,2003,15(z1):57-59. 被引量：13
  • 4Cltromel L, Volacka J, Czobor P, et al. Efficacy of ziprasidone against hostility in schizophrenia: post hoe analysis of randomized, open-label study date. J Clin Psychiatry, 2006,67 (4) : 638 642.
  • 5Simpson GM, Glick ID, Weiden PJ, et al. Randomized. controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry, 2004,161 (10) : 1837 -847.
  • 6Meyer JM, Davis VG, Goff DC, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1. Sehizopbr Res, 2008,92(1-5) :95-102.

二级参考文献35

  • 1[1]Buse JB, Cavazzoni P, Hornbuckle K, et al. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. Journal of Clinical Epidemiology, 2003, 56 : 164 ～ 170
  • 2[2]Caro J, Ward A, Levinton C, et al. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. Journal of Clinical Psychiatry, 2002, 63 : 1135 ～9
  • 3[3]Cohen S, Fitzgerlad B, Okos A, et al. Weight, lipids, glucose and behavioral measures with ziprasidone treatment in a population with mental retardation. Journal of Clinical Psychiatry, 2003, 64: 60 ～ 2
  • 4[4]de Vegt F, Dekker JM, et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population. The Hoorn Study. JAMA, 2001, 285 : 2109 ～ 13
  • 5[5]Gerstein HC, Pais P, et al. Relationship of glucose and insulin levels to the risk of myocardial infarction: a case-control study. Journal of the American College of Cardiology, 1999, 33 : 612 ～9
  • 6[6]Gianfrancesco FD, Grogg AL, Mahmoud RA, et al. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: Findings from a large health plan database. J Clin Psychiatry, 2002, 63 : 920 ～ 930
  • 7[7]Goodnick PJ, Jerry JM. Aripiprazole: profile on efficacy and safety.Expert Opinion on Pharmacotherapy, 2002, 3 : 1773 ～81
  • 8[8]Hagg S, Joelsson L, et al. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. Journal of Clinical Psychiatry, 1998, 59: 294～9
  • 9[9]Hedenmalm K, Hagg S, Stahl M, et al. Glucose intolerance with atypical antipsyehotics. Drug Saf, 2002, 25 : 1107 ～ 1116
  • 10[10]Heiskanen T, Niskanen L, et al. Metabolic syndrome in patients with schizophrenia. Journal of Clinical Psychiatry, 2003, 64 (5) : 575 ～9

共引文献12

同被引文献162

引证文献12

二级引证文献81

卒中与神经疾病
2008年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部